2010 Home  |  Day 1  |   Day 2  |  Day 3 |  Download Brochure
Speakers  |  Short Courses 

Biomarker World Congress 2010, a Big Success!

This year’s Sixth Annual Biomarker World Congress was attended by more than 350 executives, research scientists, CROs and others from public and private sectors. Held at the Loews Philadelphia Hotel, there was representation from more the 20 countries and 200 companies. This event featuring more than 60 presentations provided ample opportunity for idea sharing and networking with leaders in the field of Biomarkers. This signature event in Cambridge Healthtech Institute's Biomarker Series, the Biomarker World Congress 2010, dedicated to all areas of biomarker research spanning the pharmaceutical and diagnostic pipeline did not disappoint.

Mark your calendar for 2011, May 2-4 at the Loews Philadelphia Hotel.

Coverage Includes:

  • Implementing Personalized Medicine
  • Clinical Applications of Biomarkers
  • Biomarkers to Accelerate Drug Development
  • Translational Medicine
  • Biomarker Assay Development
  • Circulating Tumor Cells
  • Overcoming Barriers in Biomarker Implementation
  • Translating Biomarkers into Diagnostics
  • Collaborative Efforts in Biomarker Development

Pre-Conference Events:

  • Short Course: Fit-For-Purpose Biomarker
    Assay Development and Validation
  • Executive ThinkTank: Overcoming Challenges in Biomarker Implementation

Featured Speakers

Massimo Cristofanilli Massimo Cristofanilli, Chairman, Medical Oncology, Fox Chase Cancer Center

Giora FeuersteinGiora Feuerstein, President,
FARMACON, Translational Medicine
Drug Discovery and Development Consulting;Formerly, AVP & Head, Discovery Translational Medicine, Wyeth

Madhu MondalMadhu Mondal, Head, Early Toxicology, Novartis

Felix FruehFelix Frueh, VP, R&D, Personalized Medicine, Medco

Geert KolvenbagGeert J.C.M. Kolvenbag, Global Product VP, Oncology, AstraZeneca

Allen RosesAllen D. Roses, Director, Deane Drug Discovery Institute, Duke University

John WagnerJohn Wagner, VP, Clinical Pharmacology, Merck

David WholleyDavid Wholley, Director, The Biomarkers Consortium

Hans WinklerHans Winkler, Global Head, Oncology Biomarkers, Johnson & Johnson


John L. Allinson, FIBMS, Vice President, Biomarker Laboratory Services, ICON Development Solutions

Michael Amos, Ph.D., Scientific Advisor, Chemical Science & Technology Laboratory, National Institute of Standards & Technology Measurement; Ex-Officio Member, Secretary’s Advisory Committee on Genetics Health and Society (SACGHS), Department of Health and Human Services
Samuel C. Blackman, M.D., Ph.D., Associate Director, Experimental Medicine/Oncology, Merck Research Laboratories

Massimo Cristofanilli, M.D., FACP, Professor and Chairman, Department of Medical Oncology; G. Morris Dorrance Jr. Endowed Chair in Medical Oncology, Fox Chase Cancer Center (FCCC)

Viswanath Devanarayan, Ph.D., Director, Global Exploratory Statistics, Abbott Laboratories

Giora Feuerstein, M.D., President, FARMACON, LLC, Translational Medicine Drug Discovery and Development Consulting; formerly Assistant Vice President and Head, Discovery Translational Medicine, Wyeth Research

Mark Fidock, Ph.D., Head, Quantitative Biomarkers, Research Enabling Group, Pfizer Ltd.

Felix W. Frueh, Ph.D., Vice President, Research & Development, Personalized Medicine, Medco Health Solutions, Inc.

Andrew Grupe, Ph.D., Senior Director, Pharmacogenomics Research & Development, Celera Corporation

Darren Hodgson, M.D., Biomics Advisor, Oncology and Infection Therapy Area, AstraZeneca

Dave S.B. Hoon, Ph.D., Director, Department of Molecular Oncology, John Wayne Cancer Institute.

Francis Kalush, Ph.D., Network Leader, Diagnostics & Personalized Medicine, CDRH, U.S. Food and Drug Administration

Aaron B. Kantor, Ph.D., Chief Scientific Officer, Research and Development, Immune Tolerance Institute

Joe Keenan, Head, Sales and Marketing, Argutus Medical Ltd.

Geert J.C.M. Kolvenbag, M.D., Ph.D., Global Product Vice President, Oncology, AstraZeneca Pharmaceuticals, Inc.

Myla Lai-Goldman, M.D., Chief Executive Officer, CancerGuide Diagnostics, Inc.

Thomas M. Li, Ph.D., CTO and Senior Director, Technology Management, Roche Diagnostics

Michael N. Liebman, Ph.D., Managing Director, Strategic Medicine, Inc.

Robert McCormack, Ph.D., Director, Technology Assessment, Ortho Clinical Diagnostics, Veridex, LLC

Madhu Mondal, Ph.D., DABT, Head, Protein and Analytical Toxicology Laboratory, Investigative Toxicology/Preclinical Safety, Novartis Institutes of Biomedical Research, Inc.

Margaret Piper, Ph.D., MPH, Director, Genomics Resources, Technology Evaluation Center, Blue Cross Blue Shield Association

Bruce Quinn, M.D., Ph.D., Senior Health Policy Specialist, Foley Hoag; Former California Medical Director, NHIC

Donna Roscoe, Ph.D., Scientific Reviewer, DIHD/OIVD/CDRH/FDA

Allen D. Roses, M.D., Jefferson-Pilot Professor of Neurobiology and Neurology, Director, Deane Drug Discovery Institute, Duke University

Yaping Shou, M.D., Ph.D., Director, Oncology Biomarkers and Imaging, Biomarker Project Leader-Tasigna, Novartis Institutes for BioMedical Research

John Wagner, M.D., Ph.D., Vice President, Clinical Pharmacology, Merck Research Labs

Yaning Wang, Ph.D., Team Leader, Pharmacometrics, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

David Wholley, Director, The Biomarkers Consortium, Foundation for the National Institutes of Health

Hans Winkler, Ph.D., Senior Director and Global Head, Oncology Biomarkers, Johnson & Johnson Pharmaceutical R&D
Shabnam Tangri, Ph.D., Director, Clinical Science and Technology, Biogen Idec


Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag